FloBio is developing a point-of-care diagnostic platform that utilizes multiplex analysis of flowing blood to assess bleeding and thrombotic risk in real time. This technology provides clinicians with rapid, actionable information to make informed decisions in emergency and critical care settings, ultimately improving patient outcomes and cost-effectiveness.
Funding
$570K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In emergency and critical care settings, rapid diagnosis of bleeding and clotting risks is crucial for effective patient management. Current methods often lack the speed and comprehensive information needed to make timely decisions regarding hemostasis restoration. This can lead to delayed treatment and potentially adverse patient outcomes.
Solution
FloBio is developing a point-of-care diagnostic platform that performs multiplex analysis of flowing blood to provide real-time assessment of hemostasis function. The fluidic-based system delivers actionable information to clinicians, enabling quick and informed decisions regarding bleeding and thrombotic risk. By offering a comprehensive evaluation of hemostasis at the point of care, FloBio aims to improve patient outcomes and reduce healthcare costs associated with managing bleeding abnormalities. The initial test in development is designed to evaluate Direct Oral Anti-coagulant drug presence, class and level.
Target Audience
The primary target audience includes clinicians and hospitals in emergency, trauma, and critical care settings who require rapid and accurate assessment of bleeding and clotting risks.
Features
- Multiplex analysis of flowing blood for real-time hemostasis evaluation
- Fluidic-based diagnostic platform for point-of-care testing
- Rapid assessment of bleeding and thrombotic risk
- Designed for use in emergency, trauma, and critical care settings
- Early risk assessment capabilities
- Development of a portfolio of tests